Zeus Hygia Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 07-12-2024
- Paid Up Capital ₹ 7.46 M
as on 07-12-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.25 Cr
as on 07-12-2024
- Revenue -53.92%
(FY 2023)
- Profit -75.11%
(FY 2023)
- Ebitda -37.42%
(FY 2023)
- Net Worth 59.57%
(FY 2023)
- Total Assets 31.87%
(FY 2023)
About Zeus Hygia Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 7.46 M.
The company currently has active open charges totaling ₹1.25 Cr.
Shankara Jeyakodi and Arun Rajalekshmy serve as directors at the Company.
- CIN/LLPIN
U74999TN2010PTC074488
- Company No.
074488
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Zeus Hygia Life Sciences Private Limited offer?
Zeus Hygia Life Sciences Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Vitamin Powder API.
Who are the key members and board of directors at Zeus Hygia Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shankara Jeyakodi  | Director | 04-Feb-2010 | Current |
| Arun Rajalekshmy | Director | 04-Feb-2010 | Current |
Financial Performance of Zeus Hygia Life Sciences.
Zeus Hygia Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 53.92% decrease. The company also saw a substantial fall in profitability, with a 75.11% decrease in profit. The company's net worth Soared by an impressive increase of 59.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeus Hygia Life Sciences?
In 2023, Zeus Hygia Life Sciences had a public holding of 8.34%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Neovertex Laboratories Private LimitedActive 7 years 4 monthsShankara Jeyakodi and Arun Rajalekshmy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 17 Jan 2023 | ₹1.25 Cr | Open |
How Many Employees Work at Zeus Hygia Life Sciences?
Unlock and access historical data on people associated with Zeus Hygia Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeus Hygia Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeus Hygia Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
